Genetic Technologies' (ASX:GTG) GeneType test reveals 79.5% elevated risk for serious diseases

Genetic Technologies reported findings from its geneType risk assessment tests conducted in the US and Australia.

Results show that 79.5% of those tested are at elevated risk for at least one serious disease.

The geneType multi-risk test uses a non-invasive saliva sample to identify genetic predispositions to various cancers and metabolic conditions.

"The geneType multi-risk test is a major step forward in personalized medicine. These real-time results validate its utility in identifying high-risk individuals, enabling better health management," said Genetic Technologies CEO Simon Morris.